Scholarlink

<p>Parkinson’s Disease (PD) patients carrying <i>GBA1</i>-variants (GBA-PD) often show a faster cognitive decline, suggesting accelerated cholinergic degeneration. This study investigated changes over time in whole-brain cholinergic innervation within the context of dopaminergic changes and clinical outcomes in GBA-PD versus non-GBA-PD. 171 PD participants (44 GBA-PD, 127 non-GBA-PD) underwent clinical and neuropsychological assessments, brain MRI, <sup>18</sup>F-fluoroethoxy-benzovesamicol (<sup>18</sup>F-FEOBV) PET (cholinergic) and 3,4-dihydroxy-6-<sup>18</sup>F-fluoro-I-phenylalanine (<sup>18</sup>F-FDOPA) PET (dopaminergic) imaging. GBA-PD participants showed worse executive functioning than non-GBA-PD. Voxel-wise linear mixed-effects models showed that GBA-PD exhibited lower <sup>18</sup>F-FEOBV binding in the right precentral and middle frontal gyrus, independent of age and sex, despite similar cholinergic decline over time. No <i>GBA1</i>-related differences were found in dopaminergic signal or its progression. Age and time since diagnosis were associated with progressive cholinergic and dopaminergic denervation in all patients. This first dual-tracer longitudinal PET study highlights early cholinergic involvement in GBA-PD and supports further evaluation of <sup>18</sup>F-FEOBV PET as biomarker.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Modelling cholinergic and dopaminergic function over time in Parkinson’s disease with and without GBA1 variants

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月12日

查看全文
  • Sofie Slingerland,
  • Eline K. R. de Meyer,
  • Harm J. van der Horn,
  • Giulia Carli,
  • Anne C. Slomp,
  • Emile d’Angremont,
  • Jeffrey M. Boertien,
  • Ingeborg Goethals,
  • Sanne K. Meles,
  • Sygrid van der Zee,
  • Teus van Laar

摘要

Parkinson’s Disease (PD) patients carrying GBA1-variants (GBA-PD) often show a faster cognitive decline, suggesting accelerated cholinergic degeneration. This study investigated changes over time in whole-brain cholinergic innervation within the context of dopaminergic changes and clinical outcomes in GBA-PD versus non-GBA-PD. 171 PD participants (44 GBA-PD, 127 non-GBA-PD) underwent clinical and neuropsychological assessments, brain MRI, 18F-fluoroethoxy-benzovesamicol (18F-FEOBV) PET (cholinergic) and 3,4-dihydroxy-6-18F-fluoro-I-phenylalanine (18F-FDOPA) PET (dopaminergic) imaging. GBA-PD participants showed worse executive functioning than non-GBA-PD. Voxel-wise linear mixed-effects models showed that GBA-PD exhibited lower 18F-FEOBV binding in the right precentral and middle frontal gyrus, independent of age and sex, despite similar cholinergic decline over time. No GBA1-related differences were found in dopaminergic signal or its progression. Age and time since diagnosis were associated with progressive cholinergic and dopaminergic denervation in all patients. This first dual-tracer longitudinal PET study highlights early cholinergic involvement in GBA-PD and supports further evaluation of 18F-FEOBV PET as biomarker.